This project has received funding from the European Research Council (ERC) under the European Union’s
Horizon 2020 research and innovation programme
Grant agreement No. 725725


Acute myeloid leukemia (AML)


Gene mutations

Synthetic lethality

Drug development

Target therapy

Summary of the project

In the wide genomic landscape of acute myeloid leukemia (AML), a major breakthrough was the discovery in 2005, by the research group lead by Prof. Brunangelo Falini at Perugia University, of the NPM1 gene mutations as the most frequent genetic lesion in AML, accounting for about one-third of all adult AML.

P.I. Profile

The Principal Investigator (PI), Maria Paola Martelli is a MD, PhD, Associate Professor and Assistant Clinical Director at the Hematology section (Head: Prof. Brunangelo Falini), Department of Medicine, University of Perugia.

Latest news